Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01054079 · ClinicalTrials.gov registry record · Phase 2
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01054079 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants.
The verdict
NCT01054079, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- PROCEDURE quality-of-life assessment
- DRUG cinacalcet hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01054079
The ClinicalTrials.gov registry entry for NCT01054079 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01054079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01054079 about?
NCT01054079 is a clinical study titled "Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer". This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment
What is the current status of trial NCT01054079?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-09. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01054079?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), quality-of-life assessment (PROCEDURE), cinacalcet hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01054079?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.